Amgen Stock News

It appears that some investors took a pair of new and bullish pundit takes to heart. One of the pair was a famous stock picker who appears regularly on TV.

Amgen is performing well despite some headwinds, and its pipeline is progressing. Gilead Sciences' strong core franchise and diversification efforts should work wonders.

Bank of America came up with 16 names that investors should consider buying. Renaissance Macro threw out a couple of sector ideas, too.

An analyst bumped his price target higher on the shares. He didn't change his recommendation, however.

New technologies and an aging population are lifting the healthcare sector. Immunotherapy and anti-obesity drugs are leading the way.

Study Also Shows 36% Reduction in Risk of Heart Attack  Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke THOUSAND OAKS, Calif. , Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and...

Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a large study presented on Saturday.

Amgen is a biotech leader with strong sales growth, key products outperforming, and an impressive R&D pipeline fueling future prospects. Despite political headwinds and margin pressures, AMGN raised full-year guidance and is implying resilient bottom-line growth. The stock trades at a significant valuation discount to sector peers, making AMGN an attractive value play in the current environment.